EDITH LINVILLE: Open Payments
NPI 1316496326 · CROFTON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$856 in 39 payments from 14 companies in 2025. Trend: 2023 $1,132 · 2024 $1,179 · 2025 $856
Food & beverage: $856
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 7 | $172 |
| Vanda Pharmaceuticals Inc. | 5 | $159 |
| Lundbeck LLC | 7 | $109 |
| ABBVIE INC. | 4 | $79 |
| Neurocrine BioSciences, Inc. | 3 | $78 |
| Janssen Pharmaceuticals, Inc | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 2 | $44 |
| Alkermes, Inc. | 2 | $39 |
| Tris Pharma Inc | 1 | $25 |
| Luye Pharma (USA) Ltd. | 1 | $24 |
Products named: REXULTI, HETLIOZ, VRAYLAR, INGREZZA, ABILIFY MAINTENA, INVEGA SUSTENNA, ABILIFY ASIMTUFII, UZEDY.
Industry payments across MD — which companies pay providers there.
